Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 9/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RARB | P10826 | 7/20 | 0.40 |
| ▸ | RARG | P13631 | 7/20 | 0.40 |
| ▸ | RARA | P10276 | 5/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 4/20 | 0.34 |
| ▸ | RXRG | P48443 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11122818 | 0.86 | RARB (0.41) | RXRALMNARARBRARGRARA | |
| SCHEMBL16905456 | 0.85 | PRKDC (0.44) | PRKDCRXRALMNAALDH1A1MAPT | |
| SCHEMBL15614967 | 0.81 | PRKDC (0.42) | PRKDCLMNAALDH1A1MAPTHPGD | |
| SCHEMBL4711216 | 0.80 | PRKDC (0.38) | PRKDCRXRALMNAALDH1A1MAPT | |
| SCHEMBL6678059 | 0.79 | RXRA (0.49) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL4668099 | 0.79 | RXRA (0.37) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL15614973 | 0.78 | PRKDC (0.46) | PRKDCLMNAALDH1A1MAPTHPGD | |
| SCHEMBL4666462 | 0.78 | RARG (0.51) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL15614957 | 0.77 | PRKDC (0.44) | PRKDCLMNAALDH1A1MAPTHPGD | |
| SCHEMBL7223563 | 0.77 | RXRA (0.43) | RXRALMNARARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601257-B1 | AROMATIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-20200039903-A1 | AROMATIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | US | disclosed |
| US-20170170413-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20170170413-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-06-15 | — | — | US | disclosed |
| WO-2015117718-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | WO | disclosed |
| EP-1324970-B1 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | EP | disclosed |
| EP-1935869-A1 | Retinoids for the treatment of emphysema | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| EP-1935869-A1 | Retinoids for the treatment of emphysema | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| US-6777418-B2 | FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-08-17 | — | — | US | disclosed |
| US-6624188-B1 | Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and | ALLERGAN, INC. | 2003-09-23 | — | — | US | disclosed |
| EP-1324970-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | SYNTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
| WO-2002028810-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-04-11 | — | — | WO | disclosed |
| US-5498755-A | IMINE COMPOUNDS FOR SKIN DISORDERS AND ANTIINFLAMMATORY AGENTS | ALLERGAN, INC. | 1996-03-12 | — | — | US | disclosed |
| WO-1996006070-A1 | DISUBSTITUTED ARYL AND HETEROARYL IMINES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-02-29 | — | — | WO | disclosed |
| US-5475113-A | Treatment of skin disorders, skin cancer | ALLERGAN, INC. (US) | 1995-12-12 | — | — | US | disclosed |
| US-5324840-A | Skin disorders | ALLERGAN, INC. (US) | 1994-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039903-A1 | AROMATIC COMPOUNDS | PAH, ALG3, DDC | PRKDC 2020/4885RXRA 3429/4885LMNA 3645/4885 |
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | RXRA, RXRG, RXRB | PRKDC 3425/4885RXRA 1/4885LMNA 761/4885 |
| US-20170170413-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | PRKDC 3860/4885RXRA 3738/4885LMNA 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.